The next generation of targeted therapy for solid cancers
The next generation of targeted therapy for solid cancer
Offering selective and safe treatment to cancer patients. It is our daily determination
By developing a Tumor Activated TherapyTM, we aim at a high selectivity in the treatment, boosting efficacy while reducing adverse effects.
We aim at increases Patients’ Quality of Life.
We aim at improving Patients’ Quality of Life.
Cancer deaths usually result from the development of metastasis and the lack of curative approaches, at least for the most frequent tumour localisations. At this latter stage of the disease, cancer chemotherapy remains the most powerful and often the only available therapeutic approach. However, chemotherapy is not entirely effective against many solid tumours’ types. Most anticancer drugs lack any intrinsic antitumor selectivity. In turn, chemotherapy is frequently associated with severe side effects due to the destruction of normal tissues. As a result, the quantity of drugs that can be administered is usually insufficient to deliver an efficient concentration of the anticancer agent at the tumour site.
The Antibody Drug Conjugates (ADC) is facing also limitations in its activity
Moreover, the lack of selectivity of current anticancer drugs dramatically increases the risk of development of cellular resistance by tumours cells.
Hence, there is a need to develop more a selective and targeted approach for solid tumours.
Million deaths in the world due to cancer
New cancer cases are diagnosed each day worldwide
% of all cancers diagnosed are solid tumors (lung, breast, pancreas...)
% of all deaths are due to solid tumors (lung, breast, pancreas...)
An urgent need for better treatments for solid tumors
Over the past decade, scientists have been working on finding ways to specifically target solid tumors in order to reduce adverse effects and to increase treatment efficacy.
Seekyo has developed a disruptive new generation of targeted therapy: Tumor Activated Therapy
Selective to tumors
OFF / ON on site
Tumor Activated TherapyTM
Solid tumors induce modifications of their micro-environment (TME) that Seekyo targets to allow a highly selective treatment (healthy vs. cancer cells).
Seekyo's Mode of Action does not rely on any specific cancer cell hallmarks such as the expression of specific surface markers (eg. Antigens, membrane receptors…).
Therefore, Seekyo’s Tumor Activated Therapy has the potential to treat almost all solid tumors.
In contrast to Antibody Drug Conjugates (ADC), Tumor Activated Therapy does not require penetrating the cancer cell itself. This favourably increases the active agent efficacy ratio. Seekyo’s strategy includes a highly selective mechanism of drug release based on enzymatic activation, avoiding early or uncontrolled release responsible for the adverse effects. All those features allow for a much higher selective treatment, reducing adverse effects and increasing Patients’ Quality of Life.
Selectivity is key to ensure the drugs destroy only cancer cells, sparing all other tissues. At Seekyo we have developed a new approach based on
A double targeting of the Tumor Micro-Environment
We call it Smart chemotherapy.
We developed SKY01, a selective anticancer agent possessing a unique mode of action resulting from the combination of the subsequent steps:
In situ formation of a bioconjugate with endogenous albumin
Accumulation of the SKY01-albumin bioconjugate in the Tumor Micro-Environment (TME)
Specific ß-glucuronidase-catalysed release of free cytotoxic MMAE at the tumor site
Inhibition of tumor cell division by MMAE
Those steps are expected to occur independently of the tumor type, allowing for the therapy of many solid tumors.
Plateform and pipeline
Based on Seekyo’s innovative molecular platform SKYTM, we have successfully tested several combinations of active agents (cytotoxic drugs, immune-stimulants….), targeting units and cleavable linkers adapted at targeting the TME. In addition to generating promising internal leads (eg. SKY02 – immuno-stimulant) the platform has the potential to optimize existing drugs (e.g. widening the therapeutic window) for industrial partners.